Bulletin
Investor Alert

New York Markets Open in:

Market Snapshot Analyst Ratings

EyePoint Pharmaceuticals Inc.

NAS: EYPT

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
EyePoint Pharmaceuticals Inc.

After Hours

 --Quotes are delayed by 20 min

Aug 15, 2022, 7:09 p.m.

EYPT
/zigman2/quotes/210537129/composite

$

10.57

Change

-0.55 -4.95%

Volume

Volume 12,375

Quotes are delayed by 20 min

/zigman2/quotes/210537129/composite

Previous close

$ 11.11

$ 11.12

Change

+0.01 +0.09%

Day low

Day high

$10.59

$11.26

Open

52 week low

52 week high

$7.00

$21.50

Open
Income Statement Balance Sheet Cash Flow Statement

Annual Financials for EyePoint Pharmaceuticals Inc.

View Ratios
Fiscal year is January-December. All values USD millions. 20172018201920202021 5-year trend
Sales/Revenue 7.54M5.86M20.37M34.44M36.94M
Cost of Goods Sold (COGS) incl. D&A 815,000-5.15M8.28M10.64M
COGS excluding D&A --2.54M5.64M7.87M
Depreciation & Amortization Expense 815,0002.65M2.6M2.65M2.77M
Depreciation 91,000194,000144,000189,000311,000
Amortization of Intangibles 724,0002.46M2.46M2.46M2.46M
Gross Income 6.72M-15.22M26.15M26.3M
20172018201920202021 5-year trend
SG&A Expense 24.83M52.32M63.08M63.44M81.58M
Research & Development 14.41M20.82M15.37M17.42M28.5M
Other SG&A 10.42M31.5M47.71M46.02M-
Other Operating Expense -----
Unusual Expense 472,00018.89M3.81M905,000(2.07M)
EBIT after Unusual Expense (18.58M)(68M)(51.67M)(38.2M)(53.21M)
Non Operating Income/Expense 91,000(18.89M)---
Non-Operating Interest Income -734,0001.05M58,000292,000
Equity in Affiliates (Pretax) -----
Interest Expense -3.28M6.18M7.26M5.5M
Gross Interest Expense -3.28M6.18M7.26M5.5M
Interest Capitalized -----
Pretax Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Income Tax -----
Income Tax - Current Domestic -----
Income Tax - Current Foreign -----
Income Tax - Deferred Domestic -----
Income Tax - Deferred Foreign -----
Income Tax Credits -----
Equity in Affiliates -----
Other After Tax Income (Expense) -----
Consolidated Net Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Minority Interest Expense -----
Net Income (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Extraordinaries & Discontinued Operations -----
Extra Items & Gain/Loss Sale Of Assets -----
Cumulative Effect - Accounting Chg -----
Discontinued Operations -----
Net Income After Extraordinaries (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
Preferred Dividends -----
Net Income Available to Common (18.49M)(89.44M)(56.79M)(45.39M)(58.42M)
EPS (Basic) (5.20)(10.50)(5.44)(3.54)(2.03)
Basic Shares Outstanding 3.53M8.51M10.43M12.84M28.76M
EPS (Diluted) (5.20)(10.50)(5.44)(3.54)(2.03)
Diluted Shares Outstanding 3.53M8.51M10.43M12.84M28.76M
EBITDA (17.29M)(46.47M)(45.26M)(34.64M)(52.51M)
Copyright 2022 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Link to MarketWatch's Slice.